Omeros (NASDAQ: OMER) expands 2029 note repurchases and weighs new debt
Omeros Corporation is repurchasing a significant portion of its 9.50% Convertible Senior Notes due 2029 to reduce costly debt. The company expects to complete an initial repurchase of $16.0 million in principal, leaving $54.8 million outstanding, and has agreed to repurchase an additional $14.5 million, which would further reduce the outstanding amount to $40.3 million. Omeros may seek new unsecured or limited-collateral debt financing to cover the cash used for these repurchases, aiming for financing not linked to its equity.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) following a significant stock price drop. The investigation began after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Omeros's marketing authorization application for narsoplimab, a drug intended to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy. This news led to a 19.12% decline in Omeros's stock price on June 26, 2026.
Omeros stock drops 19% after EU rejects key drug application, prompting fraud investigation
Omeros Corporation's stock dropped 19.12% after the European Medicines Agency's committee issued a negative opinion on its drug narsoplimab. This rejection led to an investigation by Pomerantz LLP into potential securities fraud against Omeros and its executives. The development raises serious concerns regarding the company's regulatory strategy and the future prospects of its narsoplimab drug.
Price to earnings forward of Omeros Corporation – NASDAQ:OMER
This article provides financial information for Omeros Corporation (NASDAQ: OMER), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication, with no trades recorded. The content is presented within the context of TradingView's platform, offering various financial tools and market data services.
Price to earnings forward of Omeros Corporation – BX:3O8
The article focuses on the "Price to earnings forward" metric for Omeros Corporation (BX:3O8), listed on BX Swiss. It presents an overview of financial data for the company, indicating that the market was closed at the time of publication with no trades.
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide
Omeros Corporation's narsoplimab, branded as Yartemlea, received a negative opinion from the European Medicines Agency's Human Medicines Committee (CHMP) for its stem cell transplant-associated thrombotic microangiopathy treatment. This contrasts with its approval by the U.S. FDA in December 2025 and its subsequent launch in the U.S. market. The EMA cited concerns over study design and limited pediatric data, leading to a significant drop in Omeros' stock price, despite ongoing reimbursement progress in the U.S.
Enterprise value to EBITDA forward of Omeros Corporation – NASDAQ:OMER
This article focuses on the enterprise value to EBITDA forward metric for Omeros Corporation (NASDAQ: OMER). It is a financial data point presented within the context of a market analysis platform, likely TradingView, indicating a key valuation ratio for the pharmaceutical company. The content appears to be an isolated data display rather than an analytical report.
Price to book forward of Omeros Corporation – BX:3O8
This page from TradingView provides financial information for Omeros Corporation (BX:3O8), specifically focusing on its price-to-book forward ratio. It highlights that the market for this stock is currently closed with no trades. The site also lists various tools and services offered by TradingView related to financial markets.
Price to sales forward of Omeros Corporation – NASDAQ:OMER
The article provides a financial overview of Omeros Corporation (NASDAQ: OMER), specifically focusing on its Price to Sales (forward) metric. It mentions the stock is listed on Nasdaq and that the market was closed at the time of publication, with no trades. The content is primarily a data placeholder from TradingView, indicating a value for the Price to Sales forward along with its changes in percentage.
European regulator issues negative opinion on Omeros’ TA-TMA drug
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a negative opinion on Omeros Corporation's marketing authorization application for narsoplimab, a drug to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Omeros plans to request a re-examination of this decision. This regulatory setback follows the drug's approval by the U.S. FDA in December 2025 and previous strong stock performance, despite recent declines.
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
Omeros Corporation announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its marketing authorization application for narsoplimab (YARTEMLEA®) for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Omeros plans to request a re-examination of this opinion, including a review by an independent Ad Hoc Expert Group. Despite this setback in Europe, narsoplimab was approved by the U.S. FDA in December 2025 as the first and only treatment for TA-TMA.
Omeros drops amid EU hurdle for transplant drug (OMER:NASDAQ)
Omeros (OMER) shares dropped significantly in premarket trading after an expert panel of the EU drug regulator, the European Medicines Agency, declined to endorse the company's transplant therapy, narsoplimab. The Seattle-based biotech company released a statement regarding this development.
Omeros stock tumbles after EMA panel rejects narsoplimab application
Omeros Corporation shares fell significantly after a European Medicines Agency (EMA) panel issued a negative opinion on its marketing authorization application for narsoplimab, a drug for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Despite the drug being approved in the U.S. and Omeros planning to request a re-examination, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted the negative opinion. The company expressed disappointment, citing the lethal nature of TA-TMA and the lack of approved treatments in Europe.
Why Is OMER Stock Falling Today?
Omeros Corporation (OMER) stock is falling today after European regulators issued a negative opinion on its therapy, Yartemlea, for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The European Medicines Agency (EMA) found insufficient evidence of the drug's effectiveness, citing a lack of comparison to placebo or other treatments and questions about study conduct. Omeros has 15 days to request a re-examination, leading to an 18% drop in OMER stock and a shift in retail sentiment to "neutral."
Enterprise value to EBIT forward of Omeros Corporation – NASDAQ:OMER
The article provides a financial metric for Omeros Corporation (NASDAQ: OMER), specifically its Enterprise Value to EBIT (Earnings Before Interest and Taxes) forward ratio. This information is presented within the context of TradingView's financial data for the company. The content appears to be a stub or a data point rather than a full analytical article.
Price to book forward of Omeros Corporation – SWB:3O8
The article provides a financial overview of Omeros Corporation (SWB:3O8) on the Stuttgart Stock Exchange, focusing on its "Price to book forward" metric. It indicates that the market was closed at the time of publication and no trades had occurred. The content is primarily a data point with no further analysis or details.
[8-K] OMEROS CORP Reports Material Event
Omeros Corporation (OMER) filed an 8-K report detailing the results of its 2026 Annual Meeting of Shareholders held on June 18, 2026. Shareholders approved the election of three Class II directors, an advisory resolution on executive compensation, and the Amended and Restated Omeros Corporation Omnibus Incentive Compensation Plan. Ernst & Young LLP was also ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Form 4 Omeros Corporation For: 22 June By Investing.com
This article is a Form 4 filing for Omeros Corporation (OMER) for the date of June 22. It provides details on the insider transaction report and includes a company stock update. The article also lists current market data for various indices, commodities, bonds, and stocks.
Form 4 Omeros Corporation For: 22 June By Investing.com
This article announces the filing of a Form 4 for Omeros Corporation on June 22nd. Form 4 filings typically disclose changes in beneficial ownership of a company's securities by insiders. The article provides no further details on the specific transactions.
Omeros (NASDAQ: OMER) director receives 15,000 stock options
Omeros Corporation Director Rajiv Shah was granted stock options for 15,000 shares of common stock, with an exercise price of $10.28 per share, under the company’s non-employee director compensation policy. These options will vest the day before the 2027 annual shareholder meeting, provided Shah continues his directorship. This transaction is categorized as a grant/award rather than a market purchase or sale.
Omeros (NASDAQ: OMER) director receives 15,000-share stock option grant
Omeros Corporation director Arnold C. Hanish received a grant of stock options for 15,000 shares of common stock, with an exercise price of $10.28 per share. This grant was part of the company’s non-employee director compensation policy and was awarded in connection with the June 18, 2026 annual shareholder meeting. The options will fully vest on the day before the 2027 annual meeting, provided that Hanish continues his directorship.
Omeros (NASDAQ: OMER) director receives grant of 15,000 stock options at $10.28
Omeros Corporation director Peter A. Demopulos received a grant of 15,000 stock options at an exercise price of $10.28 per share. These options were awarded as part of the company's non-employee director compensation policy and will vest just before the 2027 annual shareholder meeting, provided his continued service. This transaction is a routine equity-based compensation grant rather than a market purchase or sale.
Omeros Plans Repurchase of Convertible Senior Notes
Omeros Corporation announced plans to repurchase up to $16.0 million of its 9.50% Convertible Senior Notes due 2029 through privately negotiated agreements. The total purchase price could reach $34.0 million, with closing expected between July 6 and July 16, 2026. This move is anticipated to reduce Omeros's convertible debt load, impacting its balance sheet and future interest obligations.
Omeros to repurchase up to $16 million in convertible notes in private deals
Omeros Corporation announced plans to repurchase up to $16 million in 9.50% Convertible Senior Notes due 2029 through private agreements. The total purchase price, including interest, is estimated at $34 million, with the final amount dependent on the company's common stock trading price. This move follows the company's recent first-quarter 2026 financial results which showed an EPS and revenue shortfall, though H.C. Wainwright maintained a Buy rating with a $40 price target.
OMER: All proposals passed as YARTEMLEA launch and pipeline advances marked a transformative year
Omeros Corporation (OMER) shareholders approved all proposals at their 2026 AGM, including director elections and compensation. The company highlighted a transformative year characterized by the launch of YARTEMLEA, improved financial health, and advancements in its pipeline. Management also addressed various shareholder concerns regarding product adoption, market competition, and capital allocation strategies.
Omeros to repurchase up to $16 million in convertible notes in private deals
Omeros Corporation announced plans to repurchase up to $16 million of its 9.50% Convertible Senior Notes due 2029 through privately negotiated agreements, with the total purchase price expected to reach approximately $34 million. This move comes after the company reported a significant earnings and revenue shortfall in Q1 2026, though analysts like H.C. Wainwright maintain a Buy rating due to ongoing commercialization efforts and anticipated data releases.
Omeros (NASDAQ: OMER) plans $16.0M buyback of 9.50% 2029 convertible notes
Omeros Corporation announced plans to repurchase up to $16.0 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 through privately negotiated agreements. The total purchase price is estimated at $34.0 million, including accrued interest, and is subject to adjustment based on the company's common stock trading price. If the full amount is repurchased, approximately $54.8 million of these notes will remain outstanding, with closing expected between July 6 and July 16, 2026.
Omeros Announces Webcast Details for Annual Meeting of Shareholders - June 15, 2026
Omeros Corporation announced it will host a live webcast of its Annual Meeting of Shareholders virtually on Thursday, June 18, 2026, at 10:00 a.m. Pacific Time. Shareholders of record as of April 17, 2026, can vote and submit questions via the virtual meeting website, while guests can attend without voting privileges. A recording of the meeting will be available on the company's investor relations page.
OMER Slides After Sharp Intraday Reversal Rattles Traders
Omeros Corporation (OMER) stock has dropped by 12.77% following intensified bearish sentiment driven by its latest clinical developments. The stock experienced significant intraday volatility, spiking above $10 before collapsing into the high $6s and then recovering to $8.75. Analysts highlight OMER's high-risk biotech position, characterized by minimal operating revenue, deeply negative operating margins, and net income inflated by a one-time gain, making it a speculative play on future clinical and regulatory milestones.
OMER Slides Sharply As Traders React To Volatile Tape
Omeros Corporation (OMER) shares dropped significantly by -12.77% due to clinical trial setbacks and deeply unprofitable core operations, despite a positive net income driven by securities gains. The stock exhibited extreme intraday volatility, plunging from over $10 to the mid-$8s, highlighting its speculative nature and high risk profile for traders. Analysts note its financial fragility and dependence on non-operating gains, advising caution and risk management given the stretched valuation and non-recurring profit drivers.
OMER Stock Slides As Volatility Grabs Traders’ Attention
Omeros Corporation (OMER) stock has dropped by 14.34% due to increased bearish sentiment regarding its lead drug prospects, despite a positive net income driven by securities gains rather than core operations. The company exhibits high volatility, with significant intraday price swings, making it a high-risk, high-reward trading vehicle for active traders. Its aggressive valuation and weak operating income amplify price movements, requiring disciplined risk management from traders.
H.C. Wainwright reiterates Omeros stock rating at buy, $40 target
H.C. Wainwright has reiterated a Buy rating and a $40.00 price target for Omeros Corp. despite the stock's recent weakness and an apparent overvaluation by InvestingPro analysis. The firm believes the market is under-appreciating Omeros's lead product, YARTEMLEA, especially given its strong early U.S. launch and differentiated mechanism. Upcoming data releases from EHA 2026 and ISTH 2026 are anticipated to further support YARTEMLEA's position in the market.
H.C. Wainwright reiterates Omeros stock rating at buy, $40 target By Investing.com
H.C. Wainwright has reiterated its Buy rating and $40 price target for Omeros Corp. (NASDAQ:OMER), despite the stock experiencing a significant year-to-date decline. The firm believes the market is under-discounting the potential of positive ravulizumab data and highlighted YARTEMLEA's strong early U.S. launch and differentiated mechanism. Omeros recently reported a Q1 2026 earnings and revenue miss, but the company remains optimistic about YARTEMLEA's commercialization and its cash position.
Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold)
Omeros Corporation is initiated with a Hold rating due to the balanced risk/reward profile following YARTEMLEA's encouraging commercial launch. While Q1 2026 sales exceeded expectations, long-term adoption and payer confidence remain concerns due to limited clinical data. The valuation appears to price in specific peak sales figures, and upcoming catalysts include J-code, NTAP, EMA decision, and ex-US partnerships.
Omeros (OMER) Q4 2025 Earnings Transcript
Omeros Corporation reported significant events in Q4 2025, including a $2.1 billion asset transaction with Novo Nordisk for zaltenibart and FDA approval for YARTEMLEA, marking the first and only approved treatment for TA-TMA. The company also announced strong initial commercial launch progress for YARTEMLEA, with rapid P&T committee approvals and high payer reimbursement rates. Financially, Omeros achieved a net income of $86.5 million, repaid substantial debt, and expects YARTEMLEA to be self-sustaining in 2026, leading to positive company cash flow by 2027.
Omeros (OMER) Q4 2025 Earnings Transcript
Omeros (OMER) announced pivotal fourth-quarter 2025 results, highlighted by the divestiture of zaltenibart rights to Novo Nordisk for up to $2.1 billion and the FDA approval and U.S. launch of YARTEMLEA for TA-TMA. The company reported a net income of $86.5 million and significantly strengthened its balance sheet by repaying substantial debt. Omeros also detailed successful early adoption and reimbursement for YARTEMLEA and provided updates on its diverse clinical pipeline.
Omeros Corp director Cable sells $87,039 in stock
Omeros Corp director Thomas J. Cable sold 7,500 shares of company stock worth $87,039 on May 22, 2026, as part of a Rule 10b5-1 trading plan. This transaction followed his exercise of vested stock options for the same number of shares. The sale occurred after a significant stock gain over the past year, though the stock recently declined and is trading above its fair value according to InvestingPro analysis.
Omeros Corp director Cable sells $87,039 in stock By Investing.com
Omeros Corp director Thomas J. Cable sold 7,500 shares of the company’s common stock for $87,039 on May 22, 2026. This transaction was part of a Rule 10b5-1 trading plan and occurred shortly after he exercised stock options. The sale comes amidst a significant stock gain over the past year, though the stock recently declined and trades above its fair value according to InvestingPro.
Omeros Corp director Cable sells $87,039 in stock
Omeros Corp director, Thomas J. Cable, sold 7,500 shares of the company's common stock for $87,039 on May 22, 2026, as part of a Rule 10b5-1 trading plan. This sale followed an exercise of vested stock options for an equal number of shares. The transaction occurs amidst a significant stock gain over the past year, though the stock has recently declined and trades above its Fair Value according to InvestingPro analysis, coinciding with the company reporting a significant miss on its first-quarter 2026 earnings.
Omeros (NASDAQ: OMER) director exercises options and sells 7,500 shares under 10b5-1 plan
Omeros (NASDAQ: OMER) director Thomas J. Cable exercised stock options for 7,500 shares at $10.84 per share and subsequently sold all 7,500 shares at a weighted average price of $11.6052 per share under a pre-established Rule 10b5-1 trading plan. After these transactions, Cable directly holds 35,067 shares of Omeros common stock. The sales ranged from $11.46 to $11.93 per share, and the options were set to expire on June 9, 2026.
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside
Omeros (OMER) stock surged in premarket trading after the FDA approved its drug, narsoplimab, for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a rare and often fatal complication. This marks the first approved treatment for this condition, potentially generating significant revenue for the company, with analysts projecting blockbuster status. Retail investors are optimistic about the stock's future performance following this landmark approval.
Number of shareholders of Omeros Corporation – TRADEGATE:3O8
The article focuses on the number of shareholders for Omeros Corporation (TRADEGATE:3O8), primarily serving as a financial data placeholder on TradingView. It indicates that specific shareholder value data for various periods is available, along with other financial information for the company.
[144] OMEROS CORP SEC Filing
This article reports on a Form 144 SEC filing by OMEROS CORP (OMER) dated May 22, 2026. The filing indicates a proposed sale of 7,500 shares of common stock with an aggregate market value of $89,700, acquired through the exercise of stock options, to be sold on NASDAQ via Morgan Stanley Smith Barney LLC. The document details the filer and issuer information, securities to be sold, and confirms no material adverse information is known by the seller that has not been publicly disclosed.
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA
Omeros has received FDA approval for YARTEMLEA (narsoplimab) as the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients. This significant milestone addresses a critical unmet medical need for a rare and life-threatening complication of stem cell transplantation, which previously had no FDA-approved therapies. The approval comes after a thorough review of clinical data demonstrating improved outcomes with the drug.
Earnings call transcript: Omeros Q1 2026: Stock dips after earnings miss
Omeros Corporation reported a significant earnings and revenue miss for Q1 2026, with an EPS of -$0.24 against a forecast of -$0.12, and revenue of $9.89 million against an expected $40.15 million. This led to a 10.03% drop in stock price in after-hours trading, despite successful commercialization efforts for its lead product, YARTEMLEA, and a strong cash position. The company is focusing on driving positive cash flow through YARTEMLEA, expanding its indications, and advancing other pipeline programs.
Omeros Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
Omeros Corporation reported a significant improvement in its financial performance for the first quarter ended March 31, 2026, moving from a net loss of USD 33.46 million in the prior year to a net income of USD 56.06 million. This resulted in basic earnings per share of USD 0.78, a notable turnaround from a basic loss per share of USD 0.58 in the same period last year. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapeutics for various diseases including complement-mediated diseases, cancers, and addictive disorders.
OMER Stock Gains Ground As Commercial Rollout Of Yartemlea Exceeds Expectations
Omeros Corporation (OMER) shares rose over 4% after the company reported strong first-quarter commercial revenue for YARTEMLEA, exceeding Wall Street expectations with $9.9 million in net sales. The adjusted net loss also narrowed, and operating expenses decreased significantly due to the sale of an experimental drug asset. The company is anticipating a European marketing authorization decision for YARTEMLEA and continues to advance its pipeline, leading to bullish sentiment among retail traders.
Omeros Corporation (NASDAQ:OMER) Q1 2026 Earnings Call Transcript
Omeros Corporation reported strong Q1 2026 results, driven by the successful launch of YARTEMLEA, its new drug for TA-TMA. The company exceeded earnings expectations, achieved $9.9 million in net revenues for YARTEMLEA, and ended the quarter with $135.3 million in cash. Omeros anticipates YARTEMLEA will become the standard of care for TA-TMA and is pursuing pipeline expansion and global partnerships.
Omeros (OMER) Q1 Profit Of US$51.2 Million Tests One Off Gain Narrative
Omeros (OMER) reported a Q1 2026 revenue of US$9.9 million and a net income from continuing operations of US$51.2 million, alongside a basic EPS of US$0.71. This strong Q1 profit challenges the narrative that the company's recent profitability is solely due to a large one-off gain of US$251.7 million from a previous period, which significantly inflated its trailing 12-month profit to US$84.0 million. Investors are now scrutinizing the durability of this Q1 profitability against balance sheet risks like negative shareholder equity and debt.
How Omeros’ (OMER) Noncash-Boosted Q1 Profit Swing Will Impact Investors
Omeros Corporation reported a significant Q1 2026 profit swing driven by noncash items, with sales of US$9.89 million and a net income of US$56.06 million. While this performance does not alter the core investment thesis around YARTEMLEA's launch, it highlights the impact of accounting adjustments on reported earnings. Investors are advised to differentiate between accounting volatility and actual product revenue growth, with current forecasts projecting substantial revenue and earnings increases by 2029.
